Faergeman, Soren L.
Evans, Hayley
Attfield, Kathrine E.
Desel, Christiane
Kuttikkatte, Subita Balaram
Sommerlund, Mette
Jensen, Lise Torp
Frokiaer, Jorgen
Friese, Manuel A.
Matthews, Paul M.
Luchtenborg, Christian
Brügger, Britta
Oturai, Annette Bang
Dendrou, Calliope A.
Fugger, Lars
Funding for this research was provided by:
Edmond J. Safra Philanthropic Foundation
Deutsche Forschungsgemeinschaft (112927078 - TRR 83)
Scleroseforeningen
Wellcome Trust (204290/Z/16/Z)
Article History
Received: 5 December 2019
Revised: 6 April 2020
Accepted: 7 April 2020
First Online: 1 May 2020
Conflict of interest
: A.B.O. has served on scientific advisory boards for Biogen Idec, Novartis and Sanofi Genzyme; has received research support from Novartis and Biogen Idec; has received speaker honoraria from Biogen Idec, Novartis and TEVA; and has received support for congress participation from, Merck, TEVA, Biogen, Roche, Novartis and Sanofi Genzyme. P.M.M. acknowledges consultancy fees from Adelphi Communications, Biogen, Celgene and Roche; honoraria or speakers’ honoraria from Biogen, Novartis and Roche; research or educational funds from Biogen, GlaxoSmithKline, Nodthera and Novartis; and he is a paid member of the scientific advisory board for Ipsen Pharmaceuticals. None of the companies had any influence over the current work. The other authors declare no competing interests.